Companies › Currax Pharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 4; Metabolic and endocrine; next expected readout Jan 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bupropion Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Obesity | Jan 2029 |
| Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Obesity | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06098079 | Naltrexone | Phase 4 | Obesity | Metabolic and endocrine | Jan 2029 |
| NCT06098079 | Bupropion | Phase 4 | Obesity | Metabolic and endocrine | Jan 2029 |
Axsome Therapeutics Trevi Therapeutics AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Adneuris Therapeutics Alkermes Boulder Care Inventage Lab. Otsuka
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.